Literature DB >> 20406046

Cardiac remodeling and MMPs on the model of chronic daunorubicin-induced cardiomyopathy in rabbits.

M Adamcová1, A Potáčová, O Popelová, M Štěrba, Y Mazurová, H Aupperle, V Geršl.   

Abstract

The matrix metalloproteinases (MMPs) play a key role during cardiac remodeling. The aim of the study was to investigate the changes in collagenous proteins and MMPs in the model of non-ischemic, anthracycline-induced chronic cardiomyopathy in rabbits using both biochemical and histological approaches. The study was carried out in three groups of Chinchilla male rabbits: 1) daunorubicin (3 mg/kg, once weekly for 10 weeks), 2) control (saline in the same schedule), 3) daunorubicin with the cardioprotectant dexrazoxane (60 mg/kg, before each daunorubicin). Morphological changes in the myocardium of daunorubicin-treated animals were characterized by focal myocardial interstitial fibrosis of different intensity. The subsequent proliferation of the fibrotic tissue was marked by an increased content of both collagen types I and III, which resulted in their typical coexpression in the majority of bundles of fibers forming either smaller or larger scars. Biochemical analysis showed a significantly increased concentration of hydroxyproline, mainly in the pepsin-insoluble fraction of collagenous proteins, in the daunorubicin-treated group (1.42+/-0.12 mg/g) as compared with the control (1.03+/-0.04 mg/g) and dexrazoxane (1.07+/-0.07 mg/g) groups. Dexrazoxane co-administration remarkably reduced the cardiotoxic effects of daunorubicin to the extent comparable with the controls in all evaluated parameters. Using zymography, it was possible to detect only a gelatinolytic band corresponding to MMP-2 (MMP-9 activity was not detectable). However, no significant changes in MMP-2 activity were determined between individual groups. Immunohistochemical analysis revealed increased MMP-2 expression in both cardiomyocytes and fibroblasts. Thus, this study has revealed specific alterations in the collagen network in chronic anthracycline cardiotoxicity in relationship to the expression and activity of major MMPs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406046     DOI: 10.33549/physiolres.931797

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  9 in total

1.  Chronic cardiotoxicity of doxorubicin involves activation of myocardial and circulating matrix metalloproteinases in rats.

Authors:  Monika Ivanová; Ima Dovinová; Ludmila Okruhlicová; Narcisa Tribulová; Petra Simončíková; Monika Barteková; Jana Vlkovičová; Miroslav Barančík
Journal:  Acta Pharmacol Sin       Date:  2012-03-26       Impact factor: 6.150

2.  Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Authors:  Steven E Lipshultz; Rebecca E Scully; Stuart R Lipsitz; Stephen E Sallan; Lewis B Silverman; Tracie L Miller; Elly V Barry; Barbara L Asselin; Uma Athale; Luis A Clavell; Eric Larsen; Albert Moghrabi; Yvan Samson; Bruno Michon; Marshall A Schorin; Harvey J Cohen; Donna S Neuberg; E John Orav; Steven D Colan
Journal:  Lancet Oncol       Date:  2010-09-16       Impact factor: 41.316

3.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

4.  Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms.

Authors:  Almudena Cascales; Francisco Pastor-Quirante; Beatriz Sánchez-Vega; Ginés Luengo-Gil; Javier Corral; Guzmán Ortuño-Pacheco; Vicente Vicente; Francisco Ayala de la Peña
Journal:  Oncologist       Date:  2013-04-10

5.  Quercetin improves postischemic recovery of heart function in doxorubicin-treated rats and prevents doxorubicin-induced matrix metalloproteinase-2 activation and apoptosis induction.

Authors:  Monika Barteková; Petra Šimončíková; Mária Fogarassyová; Monika Ivanová; Ľudmila Okruhlicová; Narcisa Tribulová; Ima Dovinová; Miroslav Barančík
Journal:  Int J Mol Sci       Date:  2015-04-13       Impact factor: 5.923

6.  Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans.

Authors:  Caroline J Zeiss; Daniel M Gatti; Olga Toro-Salazar; Crystal Davis; Cathleen M Lutz; Francis Spinale; Timothy Stearns; Milena B Furtado; Gary A Churchill
Journal:  G3 (Bethesda)       Date:  2019-08-08       Impact factor: 3.154

7.  The effects and mechanism of ginsenoside Rg1 on myocardial remodeling in an animal model of chronic thromboembolic pulmonary hypertension.

Authors:  Chang-yi Li; Wang Deng; Xiu-qing Liao; Jia Deng; Yu-kun Zhang; Dao-xin Wang
Journal:  Eur J Med Res       Date:  2013-06-05       Impact factor: 2.175

8.  Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines.

Authors:  Olga H Toro-Salazar; Ji Hyun Lee; Kia N Zellars; Paige E Perreault; Kathryn C Mason; Zhu Wang; Kan N Hor; Eileen Gillan; Caroline J Zeiss; Daniel M Gatti; Brooke T Davey; Shelby Kutty; Bruce T Liang; Francis G Spinale
Journal:  Cardiooncology       Date:  2018-05-01

9.  Extracellular matrix remodeling in animal models of anthracycline-induced cardiomyopathy: a meta-analysis.

Authors:  Jan M Leerink; Mabel van de Ruit; Elizabeth A M Feijen; Leontien C M Kremer; Annelies M C Mavinkurve-Groothuis; Yigal M Pinto; Esther E Creemers; Wouter E M Kok
Journal:  J Mol Med (Berl)       Date:  2021-05-29       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.